Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer

Table 1 Association of clinical characteristics to neoadjuvant treatment response by subtype

Characteristic	No.	% Good Response	P
ER+/HER2+ cases used for Collagen X IHC
No. of patients	50	36
RCB
0	8
1	10
2	6
3	26
Age, y			0.006
<50	18	62
≥50	32	28
Pre-Treatment Lymph Node Status			0.3
Negative	15	47
Positive	35	31
Pre-treatment Tumor Stage			0.8
T1c/T2	35	37
T3/T4	15	33
Tumor Grade			0.35
2	21	28.6
3	29	41.4
colXα1			0.000^a
0	9	87.5
1	17	58.8
2	9	0
3	15	0
sTIL			0.007^a
0 ≤ 10 %	20	15
11 ≤ 20 %	9	22
21 ≤ 30 %	5	40
31 ≤ 40 %	7	42
41 ≤ 50 %	7	86
51 ≤ 60 %	2	100
>60 %	0
Stroma			0.005^a
0	2	100
1	23	52
2	25	16
All ER+/Her2+ Cases
No. of patients	74	41
RCB			N/A
0	14
I	16
II	11
III	33
Age, y
<50	35	51	0.07
≥50	39	31	0.07
Pre-Treatment Lymph Node Status			0.47
Negative	26	46
Positive	48	38
Tumor Grade			0.33
2	25	32
3	49	45
Pre-treatment Tumor Stage			0.09
T1c/T2	51	47
T3/T4	23	26
sTIL			0.000^a
0 ≤ 10 %	27	11
11 ≤ 20 %	15	40
21 ≤ 30 %	8	37.5
31 ≤ 40 %	10	60
41 ≤ 50 %	12	83
51 ≤ 60 %	2	100
>60 %	0
Stroma			0.000^a
0	6	100
1	39	51.3
2	29	14.0

ISSN: 1471-2407